Akoya Biosciences (AKYA) Expected to Announce Quarterly Earnings on Monday

Akoya Biosciences (NASDAQ:AKYA) is anticipated to post its quarterly earnings results before the market opens on Monday, March 3rd. Analysts expect Akoya Biosciences to post earnings of ($0.15) per share and revenue of $21.34 million for the quarter.

Akoya Biosciences Stock Down 0.2 %

AKYA opened at $2.06 on Monday. The business’s fifty day moving average is $2.58 and its two-hundred day moving average is $2.61. The company has a debt-to-equity ratio of 5.62, a quick ratio of 1.85 and a current ratio of 2.75. The company has a market cap of $101.87 million, a price-to-earnings ratio of -1.74 and a beta of 1.23. Akoya Biosciences has a one year low of $1.88 and a one year high of $6.31.

Analyst Ratings Changes

Several equities research analysts recently commented on AKYA shares. Canaccord Genuity Group lowered shares of Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price target (down previously from $4.00) on shares of Akoya Biosciences in a report on Tuesday, November 19th. Finally, Craig Hallum lowered Akoya Biosciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $7.00 to $5.00 in a research note on Friday, November 15th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Akoya Biosciences has a consensus rating of “Hold” and a consensus target price of $5.43.

Hedge Funds Weigh In On Akoya Biosciences

An institutional investor recently raised its position in Akoya Biosciences stock. Bank of America Corp DE boosted its position in Akoya Biosciences, Inc. (NASDAQ:AKYA) by 39.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 29,092 shares of the company’s stock after acquiring an additional 8,258 shares during the period. Bank of America Corp DE owned about 0.06% of Akoya Biosciences worth $67,000 at the end of the most recent reporting period. 79.42% of the stock is currently owned by hedge funds and other institutional investors.

Akoya Biosciences Company Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.